Business Strategy : Global Cancer Supportive Care Therapeutics Market 2019 to 2022

ResearchMoz presents professional and in-depth study of "Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets".

The cancer supportive care product market consists of drugs intended to prevent or treat the symptoms of cancer, and reduce the side effects of cancer treatments. Instead of extending a patient’s life expectancy, the emphasis is on improving overall quality of life. The key indications covered in this report are cancer pain, oral mucositis, chemotherapy-induced neutropenia (CIN), chemotherapy-induced anemia (CIA), chemotherapy-induced nausea and vomiting (CINV) and bone metastasis.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1065936

These indications are not only distressing for patients, but can also lead to treatment cessation, which in turn increases patient mortality. As the number of people being diagnosed with cancer grows and access to effective treatment that allows patients to survive longer increases, demand for safe and effective cancer supportive care drugs will rise.

The majority of indications targeted by cancer supportive care products are the direct result of a patient receiving chemotherapy in an attempt to cure their cancer or relieve symptoms. It is often the case that the most effective chemotherapy regimens result in the most severe symptoms. This increases the need for cancer supportive care products, which can improve patient outcomes by providing greater tolerance to the most effective regimens. Bone metastasis and most forms of cancer pain are not caused by chemotherapy or cancer treatment, and are instead often a symptom of the cancer itself, occurring in a high proportion of cancer patients.

The level of unmet need within the cancer supportive care therapy area varies between indications. CIN and CINV both already have treatment regimens that can significantly decrease the incidence rate. However, the level of unmet need for CIA, cancer pain, oral mucositis and bone metastasis is high, with treatment focusing heavily on alleviating the symptoms instead of treating the underlying cause.

There are 245 products in active development in the cancer supportive care pipeline, but this includes products in development for smaller and less commercially significant indications. There are 169 products in active development for the key indication examined in this report, giving an average of 28 products per indication, the majority of which are at an early stage of development.

Scope

The cancer supportive care market already contains some commercially successful products.

    Which classes of drug dominate the market?
    Which indication is the most commercially successful?
    How will commercially successful drugs perform over the forecast period?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-cancer-supportive-care-therapeutics-market-to-2022-patent-expirations-create-opportunities-for-biosimilars-in-the-chemotherapy-induced-anemia-and-neutropenia-markets-report.html/toc

The cancer supportive care pipeline is relatively small, but there is significant diversity in terms of molecule types and targets.

    Which molecular targets appear most frequently in the pipeline?
    What are the commercial prospects for the most promising late-stage pipeline products?

The cancer supportive care market is forecast to grow from $11.7 billion in 2015 to $12.4 billion in 2022, at a compound annual growth rate of 0.9%.

    Which products are forecast to drive growth?
    Will generic and biosimilar competition have a significant impact on the market over the forecast period?

The company landscape is becoming increasingly competitive.

    What are the leading companies in terms of market share?
    Which companies are forecast to experience the greatest growth in market share?
    What are the drivers of growth for key companies in the market?
    How dependent are the key companies on this disease cluster for revenue?

Reasons to buy

This report will allow you to -

    Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report
    Understand the current treatment landscape, with profiles of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
    Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
    Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1065936

    Identify the leading companies in the market, in terms of market share and growth. Company analysis illustrates how dependent the key companies in the market are on revenue derived from cancer supportive care products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
    Identify commercial opportunities in the cancer supportive care deals landscape by analyzing trends in licensing and co-development deals.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Breast Cancer Market : Popular Trends & Technological advancements to Watch Out for Near Future; Global Industry Analysis 2021

ResearchMoz presents professional and in-depth study of "Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)".

Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=964493

Although, less commonly, breast cancer can also instigate in the stromal tissues, which include the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, radiation therapy, family history and personal history are linked to the growth of breast cancer.

The global market for breast cancer has grown swiftly over the past few years driven by introduction of several new drugs and biosimilars. The overall breast cancer market remained mainly dominated by the generic drugs. The future market for breast cancer will grow in the coming years as there exist unmet need for new drugs that would overcome resistance and prevent recurrence of the disease.

The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, clinical trials of CDK4/6 inhibitors and introduction of new imaging tests. However, growth of the market can be hindered by several factors including drug development challenges in developing countries, long term side effects of drugs and heavy costs associated with drug development.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20172021-report.html/toc

The report “Global Breast Cancer Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.

Table of Content

1. Introduction
1.1 Market Overview

2. Global Breast Cancer Market
2.1 Global Breast Cancer Market by Value
2.2 Global Breast Cancer Market Forecast by Value
2.3 Global Breast Cancer Market by Region
2.4 Global Breast Cancer Drug Development by Stages

Browse Report @ https://www.researchmoz.us/global-breast-cancer-market-industry-analysis-outlook-20172021-report.html

3. Regional Breast Cancer Market
3.1 The U.S.
3.1.1 The U.S. Breast Cancer Market by Value
3.1.2 The U.S. Breast Cancer Market Forecast by Value
3.1.3 The U.S. Breast Cancer Market by Addressable Population
3.1.4 The U.S. Breast Cancer Market Forecast by Addressable Population
3.1.5 The U.S. Breast Cancer Population by Age
3.2 Europe
3.2.1 EU5 Breast Cancer Market by Value
3.2.2 EU5 Breast Cancer Market Forecast by Value

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Research of Breast Cancer Market in Global Industry : Market Demands, Insights, Research and Forecast 2017

ResearchMoz presents professional and in-depth study of "Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes".

The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=668359

The degree and proportion of breakthrough innovations in this pipeline is exceptional & GBI Research analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products with a disclosed molecular target, and is reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as despite the high attrition rate in breast cancer, it is highly likely many of the first-in-class products will reach the market over the coming decade and, will have the opportunity to transform the clinical and commercial landscape.

Potential driving factors behind this market include a very large and growing patient pool, a well-established disease market with a number of strong unmet needs, and the strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fill the unmet needs.

Some 289 first-in-class products that are currently in development have not yet been involved in licensing or co-development deals, meaning there are numerous opportunities for in-licensing or co-development in this indication, which already has a strong track record of breakthrough innovation yielding highly commercially and clinically successful therapies.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/frontier-pharma-breast-cancer-firstinclass-innovation-clustered-around-growth-factor-signalling-processes-report.html/toc

Scope

    The report analyzes innovation in breast cancer, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products in breast cancer, and pinpoints opportunities for in-licensing.
    A brief introduction to breast cancer, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
    The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
    Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
    Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
    Assessment of the licensing and co-development deal landscape for breast cancer therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products.

Browse Report @ https://www.researchmoz.us/frontier-pharma-breast-cancer-firstinclass-innovation-clustered-around-growth-factor-signalling-processes-report.html

Reasons to buy

    Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
    Visualize the composition of the breast cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
    Analyze the breast cancer pipeline, stratified by stage of development, molecule type and molecular target.
    Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
    Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals, and producing a list of breast cancer therapies that are not yet involved in deals and may be potential investment opportunities.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets : Market Trends, Analysis, Growth and Status 2017-2022

ResearchMoz presents professional and in-depth study of "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market".

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=725317

Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Xalkori and Gilotrif. Opdivo (nivolumab) - a mAb immune checkpoint inhibitor targeted towards Programmed cell Death (PD) 1 - is a recent market entrant, gaining approval for treating advanced or metastatic squamous NSCLC patients in Japan in 2015 and in Australia in 2016. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Therapies that target mutant T790M and KRAS are being developed in the pipeline, with osimertinib, targeting T790M, gaining approval in Japan in 2016.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/nonsmall-cell-lung-cancer-therapeutics-in-asiapacific-markets-to-2022-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market-report.html/toc

Scope

The NSCLC Asia-Pacific market will be valued at $4.9 billion in 2022, growing from $2.7 billion in 2015 at a CAGR of 8.7%.

    How will immunotherapies such as Keytruda contribute to the growth?
    What effect will patent expirations of currently branded therapies have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.

    What are the common targets and mechanisms of action of pipeline therapies?
    Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
    What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

    How have the late-stage therapies performed in clinical trials?
    How would the approval of rociletinib to treat T790M mutant patients affect the competitive landscape, with its competitor osimertinib (AZD-9291) already approved in Japan in 2016?
    How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

      How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
      How could changes in risk factors such as population age, smoking habits and pollution influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

      How do deal frequency and value compare between target families and molecule types?
      What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -

    Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
    Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
    Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
    Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

Browse Report @ https://www.researchmoz.us/nonsmall-cell-lung-cancer-therapeutics-in-asiapacific-markets-to-2022-launch-of-premium-targeted-therapies-and-increasing-prevalence-to-drive-the-market-report.html

    Predict NSCLC market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
    Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Development of HER2-Negative Breast Cancer Market in US Drug Industry : Growth and Status 2017

ResearchMoz presents professional and in-depth study of "HER2-Negative Breast Cancer - US Drug Forecast and Market Analysis to 2023".

Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-negative breast cancer market, with coverage of multiple settings; neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Overall five year survival in breast cancer is relatively high, at around 90%, but this is subjective to the subtype and stage of the disease. Importantly this report segments HER2 negative breast cancer into its two major subtypes; hormone receptor positive (HR+) and triple negative breast cancer (TNBC).

The US will remain the largest HER2-negative breast cancer market throughout the forecast period. The growth of this market will be driven by the high incidence of HER2-negative breast cancer in the US, which almost equals that of the entire 5EU, combined with the higher treatment rates in the neoadjuvant and adjuvant settings and the influx of premium-priced products over the forecast period. In particular, the prices for both the current and pipeline therapies are the highest in the world, which is due to the private health insurance system in the US, which can more easily afford to reimburse the latest expensive drugs than the healthcare systems in other countries.

Scope

- Overview of HER2-Negative Breast Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product HER2-Negative Breast Cancercription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US HER2-Negative Breast Cancer market.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=845847

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HER2-Negative Breast Cancer.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US.

Table Of Contents

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 9

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 12

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Basic Breast Anatomy 15
3.2 Disease Classification/Staging Systems 16
3.3 Symptoms 18
3.4 Prognosis 18
3.5 Quality of Life 19

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=845847

4 Disease Management 22
4.1 Diagnosis and Treatment Overview 22
4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 22
4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC) 24
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 28

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer : Key Trends, Challenges and Standardization 2017

ResearchMoz presents professional and in-depth study of "Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020)".

The report entitled Global Cancer Diagnostic Market with Focus on Lung and Breast Cancer (2016-2020), provides analysis of the global cancer diagnostics market and the US cancer diagnostics market, with detailed analysis of market size and growth, penetration and market share. The report also provides the analysis of the global and the US cancer market, by prevalence, new cases, deaths, type of cancers, etc. The report provides the market sizing of the global lung and breast cancer diagnostic market by value and by segments.

The report also discusses about the different diagnostic test of lung cancer and breast cancer. The diagnostics test analyzed in the report are: MetaStat (Meta Test) (Breast Cancer Test), OncotypeDX (Breast Cancer Test), OncoCyte (Lung Cancer Test), Veracytes Test (Lung Cancer Test) and Integrated Diagnostics, Inc. Test (Lung Cancer Test).

Country Coverage

North America (US)

Executive Summary

A disease caused by abnormal growth of cells in the body, is called Cancer. In this disease, the formation of new cells slows or start dividing, forming lumps. However, all lumps are not cancerous; and this can be known by diagnosis.

There are various types of cancer- prostate cancer, breast cancer, lung and bronchus cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-hodgkin lymphoma, kidney and renal, pelvis cancer, thyroid cancer, endometrial cancer and others.

Cancer is diagnosed using various tools, which confirm the presence of tumour, and the rate of its growth within the body. Cancer diagnosis can be segmented into: imaging testing, endoscopy, biopsy and tumour marker. Each segment can be sub segmented.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=841071

The global cancer diagnostic market is expected to increase at a significant growth rate during the forecasted period (2016-2020). The global cancer diagnostic market is supported by various growth drivers, such as the rising incidence of cancer, sedentary lifestyle, growing technological advancement, increasing awareness, etc.

Table Of Contents

1. Executive Summary

2. Introduction

2.1 Cancer Overview
2.2 Cancer Diagnostic: Overview
2.3 Cancer Diagnostic: Liquid Biopsy

3. Market Analysis

3.1 Cancer Prevalence Analysis
3.1.1 Global Cancer New Cases and Death
3.1.2 Global Cancer Prevalence, New Cases and Death by Type
3.1.3 US Cancer Prevalence
3.1.4 US Cancer New Cases and Death by Type

3.2 Cancer Diagnostic Market Analysis
3.2.1 Global Cancer Diagnostic Market by Value
3.2.2 Global Cancer Diagnostic Market by Segments (Type of Tests)
3.2.3 Global Cancer Diagnostic Market by Segments (Type of Cancer)
3.2.4 Global Cancer Diagnostic Market by Region
3.2.5 North America Cancer Diagnostic Market by Value

3.3 Lung Cancer Diagnostic Market Analysis
3.3.1 Global Lung Cancer Diagnostic Market by Value
3.3.2 Global Lung Cancer Diagnostic Market by Segment (Type of Test)
3.3.3 Global Lung Cancer Cases by Type

3.4 Breast Cancer Diagnostic Market Analysis
3.4.1 Global Breast Cancer Diagnostic Market by Value

3.5 MetaStat (Meta Test) Analysis (Breast Cancer Test)
3.5.1 Mena Testing: An Overview
3.5.2 Mena Breast Cancer Test Market Opportunity (US)
3.5.3 US Mena Test Market Opportunity
3.5.4 US Mena Test Market by Number of Test and Addressable Population

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=841071

3.6 OncotypeDX (Breast Cancer Test)
3.6.1 OncotypeDX by Addressable Market

3.7 OncoCyte (Lung Cancer Test)
3.7.1 OncoCyte Test by Average Price and Revenue
3.7.2 OncoCyte Test by Test Volume and Market Penetration

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

Bladder Cancer - Epidemiology : Market Development, Analysis and Overview 2017-2025

ResearchMoz presents professional and in-depth study of "EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025".

Bladder cancer is a commonly diagnosed cancer and causes significant numbers of cancer deaths worldwide. The major risk factors for bladder cancer are exposure to smoking and occupational risk factors such as exposure to aromatic amines. These risk factors are more prevalent among men, which makes the disease significantly more common in men than women. The majority of bladder cancer cases are among older individuals, with the median age at diagnosis being 73 years; because of this, the comorbidities associated with bladder cancer are similar to conditions typically occurring in older age, and therefore are not specific to bladder cancer.

GlobalData epidemiologists forecast that by 2025, the 7MM are expected to have 289,623 diagnosed incident cases of bladder cancer, representing a 23.5% increase from the number of incident cases in 2015 (234,581 incident cases). In 2015, the 7MM had 873,493 five-year diagnosed prevalent cases of bladder cancer and GlobalData epidemiologists forecast that by 2025, this number will grow to 1,094,707 five-year diagnosed prevalent cases at an Annual Growth Rate (AGR) of 2.53%.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=915866

This forecast is supported by at least 10 years of historical data obtained from country-specific studies published by the World Health Organizations (WHO) International Agency for Research on Cancer (IARC), the National Cancer Institutes (NCI) Surveillance, Epidemiology, and End Results (SEER) program, the European Cancer Registrys fifth database registry (EUROCARE-5), the Center for Cancer Control and Information Services, National Cancer Center (CCCIS, NCC) in Japan, as well as country-specific cancer registries. Another major strength of this analysis is that GlobalData epidemiologists were able to forecast incident cases of bladder cancer in the 7MM by age, sex, and stage at diagnosis. Furthermore, the forecast methodology was consistent across all markets, thereby allowing for a meaningful global comparison.

Scope

- The Bladder Cancer EpiCast Report provides an overview of the risk factors and global trends of bladder cancer in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of bladder cancer segmented by sex, age (beginning at 15 years and ending at =75 years), and cancer stage at diagnosis (stage 0, stage I, stage II, stage III, and stage IV), in addition to five-year diagnosed prevalent cases in these seven markets.
- The bladder cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=915866

Reasons to buy

The Bladder Cancer EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global bladder cancer market.
- Quantify patient populations in the global bladder cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for bladder cancer therapeutics in each of the markets covered.
- Identify the percentage of bladder cancer diagnosed incident cases by stage.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://mymarketresearchlifereports.blogspot.in/

Analysis of Small-Cell Lung Cancer : Market Development and Overview 2017

ResearchMoz presents professional and in-depth study of "Small-Cell Lung Cancer - Pipeline Review, H2 2016".

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer Pipeline Review, H2 2016, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.

Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 42, 25, 3, 37 and 6 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.Small-Cell Lung Cancer.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=889479

Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=889479

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://mymarketresearchlifereports.blogspot.in/

Overview of Pancreatic Cancer : Market Development, Analysis and Demand 2017

ResearchMoz presents professional and in-depth study of "Pancreatic Cancer - Pipeline Review, H2 2016".

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer Pipeline Review, H2 2016, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 15, 106, 112, 1, 3, 249, 38 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 7, 50 and 7 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=905718

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=905718

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://mymarketresearchlifereports.blogspot.in/